China · Delayed Price · Currency is CNY Newland Pharmaceutical Statistics
Total Valuation
SHE:301277 has a market cap or net worth of CNY 4.52 billion. The enterprise value is 3.86 billion.
| Market Cap | 4.52B |
| Enterprise Value | 3.86B |
Important Dates
The last earnings date was Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Apr 30, 2026 |
Share Statistics
SHE:301277 has 392.08 million shares outstanding. The number of shares has decreased by -0.94% in one year.
| Current Share Class | 392.08M |
| Shares Outstanding | 392.08M |
| Shares Change (YoY) | -0.94% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 63.76% |
| Owned by Institutions (%) | 0.39% |
| Float | 98.88M |
Valuation Ratios
The trailing PE ratio is 44.75.
| PE Ratio | 44.75 |
| Forward PE | n/a |
| PS Ratio | 6.85 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 74.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.34, with an EV/FCF ratio of -1,352.98.
| EV / Earnings | 38.26 |
| EV / Sales | 5.85 |
| EV / EBITDA | 24.34 |
| EV / EBIT | 38.92 |
| EV / FCF | -1,352.98 |
Financial Position
The company has a current ratio of 6.35, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.35 |
| Quick Ratio | 5.95 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | -0.65 |
| Interest Coverage | 868.89 |
Financial Efficiency
Return on equity (ROE) is 6.23% and return on invested capital (ROIC) is 10.10%.
| Return on Equity (ROE) | 6.23% |
| Return on Assets (ROA) | 3.39% |
| Return on Invested Capital (ROIC) | 10.10% |
| Return on Capital Employed (ROCE) | 6.03% |
| Weighted Average Cost of Capital (WACC) | 6.71% |
| Revenue Per Employee | 672,311 |
| Profits Per Employee | 102,729 |
| Employee Count | 981 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 9.33 |
Taxes
In the past 12 months, SHE:301277 has paid 11.76 million in taxes.
| Income Tax | 11.76M |
| Effective Tax Rate | 10.59% |
Stock Price Statistics
The stock price has decreased by -4.06% in the last 52 weeks. The beta is 0.45, so SHE:301277's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -4.06% |
| 50-Day Moving Average | 12.07 |
| 200-Day Moving Average | 13.08 |
| Relative Strength Index (RSI) | 41.79 |
| Average Volume (20 Days) | 3,290,859 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301277 had revenue of CNY 659.54 million and earned 100.78 million in profits. Earnings per share was 0.26.
| Revenue | 659.54M |
| Gross Profit | 203.79M |
| Operating Income | 99.39M |
| Pretax Income | 111.08M |
| Net Income | 100.78M |
| EBITDA | 156.25M |
| EBIT | 99.39M |
| Earnings Per Share (EPS) | 0.26 |
Balance Sheet
The company has 666.23 million in cash and 1.86 million in debt, with a net cash position of 664.37 million or 1.69 per share.
| Cash & Cash Equivalents | 666.23M |
| Total Debt | 1.86M |
| Net Cash | 664.37M |
| Net Cash Per Share | 1.69 |
| Equity (Book Value) | 1.59B |
| Book Value Per Share | 4.05 |
| Working Capital | 931.71M |
Cash Flow
In the last 12 months, operating cash flow was 60.92 million and capital expenditures -63.77 million, giving a free cash flow of -2.85 million.
| Operating Cash Flow | 60.92M |
| Capital Expenditures | -63.77M |
| Depreciation & Amortization | 56.86M |
| Net Borrowing | -1.80M |
| Free Cash Flow | -2.85M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 30.90%, with operating and profit margins of 15.07% and 15.28%.
| Gross Margin | 30.90% |
| Operating Margin | 15.07% |
| Pretax Margin | 16.84% |
| Profit Margin | 15.28% |
| EBITDA Margin | 23.69% |
| EBIT Margin | 15.07% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 111.16% |
| Buyback Yield | 0.94% |
| Shareholder Yield | 2.67% |
| Earnings Yield | 2.23% |
| FCF Yield | -0.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2025. It was a forward split with a ratio of 1.4.
| Last Split Date | Apr 16, 2025 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |